A fast-growing market for compounded GLP-1 drugs is exposing serious gaps in federal oversight, as illicit foreign active pharmaceutical ingredients continue to appear in products sold to American patients. The problem sits at the intersection of soaring demand, aggressive compounders, and an enforc ement system that critics say has moved too slowly to stop questionable ingredients […] Illicit Foreign Ingredients Feed A Troubling GLP-1 Compounding Market ...read more read less